A subscription to JoVE is required to view this content. Sign in or start your free trial.

Research Article

Hesperidin Mitigates Skeletal Muscle Ischemia–Reperfusion Injury via Nrf2, NF-κB, and NLRP3 Pathways

65 views

⸱

DOI:

10.3791/72823

⸱

September 22nd, 2026

In This Article

Summary

This study demonstrates that hesperidin pretreatment protects rat skeletal muscle against tourniquet-induced ischemia–reperfusion injury by enhancing Nrf2-mediated antioxidant defenses while attenuating NF-κB-associated inflammation and NLRP3/caspase-1-associated pyroptotic and apoptotic responses.

Abstract

The application of tourniquets during limb surgery can lead to ischemia–reperfusion (IR) injury, a pathological process characterized by excessive oxidative stress, increased inflammatory signaling, and progressive muscle fiber damage. Hesperidin, a bioactive flavonoid derived from citrus fruits, is known for its antioxidant and anti-inflammatory properties. This study evaluated the protective effects of hesperidin against lower-limb skeletal muscle IR injury and investigated the molecular pathways potentially associated with these effects. Male Wistar rats were allocated to four groups: control, hesperidin alone, IR (2 h of ischemia followed by 2 h of reperfusion), and IR + hesperidin (100 mg/kg administered 30 min before ischemia). Histological examination of the gastrocnemius muscle was performed, and plasma markers of muscle injury, including creatine kinase (CK), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP), were measured. Oxidative stress and antioxidant parameters (MDA, SOD, CAT, and GPx), components of the Nrf2/HO-1/NQO1 pathway, inflammatory mediators (NF-κB, TNF-α, IL-6, and IL-1β), pyroptosis-associated markers (NLRP3 and caspase-1), and apoptosis-associated proteins (Bax and caspase-3) were also assessed. IR resulted in pronounced muscle fiber disruption, elevated plasma injury markers, increased lipid peroxidation, and reduced antioxidant capacity. IR also decreased Nrf2, HO-1, and NQO1 levels while increasing NF-κB, NLRP3, caspase-1, pro-inflammatory cytokines, and apoptosis-associated proteins. Hesperidin pretreatment markedly attenuated these changes by preserving muscle structural integrity, reducing plasma injury markers and lipid peroxidation, restoring antioxidant enzyme activity, increasing Nrf2/HO-1/NQO1-associated antioxidant responses, and reducing NF-κB-associated inflammatory, NLRP3/caspase-1-associated pyroptotic, and apoptotic responses. Overall, hesperidin pretreatment protected skeletal muscle against tourniquet-induced IR injury and was associated with enhanced Nrf2-mediated antioxidant defenses and attenuation of NF-κB-associated inflammation and NLRP3/caspase-1-associated responses. These findings support further investigation of hesperidin as a potential prophylactic intervention for reducing tourniquet-associated lower-limb IR injury.

Introduction

In orthopedic and other extremity surgeries, tourniquets are commonly applied to create a bloodless operative field, typically for 1–2 h and occasionally for up to 3 h, thereby improving surgical accuracy. Although effective, tourniquet application inevitably induces localized ischemia followed by reperfusion, a sequence that can result in ischemia–reperfusion injury (IRI). Studies across multiple organ systems have demonstrated that IRI is characterized by an inflammatory response initiated upon restoration of blood flow to previously oxygen-deprived tissue. Notably, tissue damage occurring during reperfusion may exceed that sustained during the ischemic period itself1,2. Clinically, tourniquet use has been associated with persistent postoperative pain lasting 2–6 weeks3,4, increased limb edema at follow-up intervals of 2 and 6 weeks5,6, and delayed functional recovery, including reduced joint mobility and quadriceps weakness that may persist for several weeks6.

During the ischemic phase, mitochondrial oxidative phosphorylation is suppressed, forcing cells to shift toward anaerobic metabolism and disrupting electron transport. As ATP stores decline, Na⁺/K⁺-ATPase activity becomes insufficient, resulting in the intracellular accumulation of Ca2⁺, H⁺, and Na⁺. Excess intracellular calcium destabilizes cellular membranes, impairs mitochondrial integrity, and activates inflammatory and apoptotic signaling cascades7. Upon restoration of blood flow, a surge in reactive oxygen species (ROS), complement activation, and leukocyte recruitment further exacerbates tissue injury8,9. ROS promote leukocyte activation, chemotaxis, cytokine gene transcription, and NF-κB-associated signaling, thereby contributing to cellular damage. Complement activation and the release of pro-inflammatory mediators, including TNF-α, IL-1, and IL-6, further impair microvascular perfusion10. Infiltrating leukocytes subsequently release ROS, proteases, and elastases into the interstitial space, increasing vascular permeability and promoting edema, thrombosis, and parenchymal cell death11.

Hesperidin, a flavanone glycoside abundant in citrus fruits, is widely recognized for its antioxidant, anti-inflammatory, and anticancer properties. Recent studies have shown that hesperidin can attenuate oxidative stress and inflammatory responses associated with IRI12,13. Hesperidin has also demonstrated protective effects against chemically induced liver injury and has been reported to inhibit hepatocarcinogenesis by modulating oxidative stress, inflammation, and abnormal cell proliferation14. Based on this evidence, the hypothesis of the present study was that hesperidin pretreatment would attenuate skeletal muscle ischemia–reperfusion injury in a rat tourniquet model by enhancing Nrf2/HO-1/NQO1-associated antioxidant defenses while attenuating NF-κB-associated inflammation, NLRP3/caspase-1-associated pyroptotic responses, and apoptotic signaling. Accordingly, the present study evaluated the protective effects of hesperidin against lower-limb skeletal muscle ischemia–reperfusion injury and investigated the molecular pathways potentially associated with its antioxidant and anti-inflammatory effects, with particular emphasis on the Nrf2/HO-1/NQO1, NF-κB, and NLRP3/caspase-1 pathways.

Access restricted. Please log in or start a trial to view this content.

Protocol

All experimental procedures involving animals were approved by the Ethics Committee of Umm Al-Qura University, Saudi Arabia (approval code: HAPO-02-K-012-2026-05-3459). All procedures were conducted in accordance with the institutional guidelines for the care and use of laboratory animals.

Animals

Adult male Wistar albino rats, 3–4 months of age and weighing an average of 322 ± 12 g, were used in the study. The animals were housed 10 per type IV cage on wood-shaving bedding and maintained at 24°C under a 12 h light/dark cycle, with unrestricted access to standard laboratory chow and water. Before the experimental procedures, all animals were fasted overnight but were allowed unrestricted access to water.

Experimental groups and induction of ischemia–reperfusion

Animals were randomly assigned to four experimental groups, with 10 rats in each group. Randomization was performed using a computer-generated random-number sequence. Anesthesia was induced by intraperitoneal administration of xylazine (8 mg/kg) and ketamine (60 mg/kg). Except for the control and hesperidin-only groups, ischemia was induced by placing a tightly secured rubber tourniquet around the proximal region of the left hind limb to occlude the common femoral artery and its collateral branches. A rubber tourniquet (width 5 mm) was applied around the proximal left hind limb at the level of the greater trochanter. Occlusion was standardized by applying a consistent tension using a spring tension gauge set at 2.5 N, ensuring complete occlusion of the common femoral artery and its collateral branches. Successful induction of ischemia was confirmed by limb cyanosis and a noticeable decrease in surface temperature. After 2 h of ischemia, the tourniquet was removed, and reperfusion was allowed to proceed for an additional 2 h. Reperfusion was confirmed by restoration of limb warmth and normal pink coloration, the presence of a palpable pulse, and a reduction in edema, consistent with previously described criteria15,16. Subsequent experimental analyses were performed by evaluators blinded to the treatment conditions.

The control group (C; n = 10) received 0.50 mL of 0.5% carboxymethylcellulose (CMC) orally by gavage, 30 min before the sham procedure. These animals were anesthetized and handled in the same manner as the other groups, but were not subjected to tourniquet application, ischemia, or reperfusion. The hesperidin group (Hes; n = 10) received a single oral dose of hesperidin (100 mg/kg) dissolved in 0.5% carboxymethylcellulose (CMC) in distilled water by oral gavage 30 min before the sham procedure, following the regimen reported by Park et al.17 in a liver ischemia–reperfusion model. These animals underwent anesthesia and identical handling procedures but were not subjected to ischemia or reperfusion. This group was included to assess the baseline physiological effects of hesperidin alone.

The ischemia–reperfusion group (IR; n = 10) underwent 2 h of tourniquet-induced ischemia followed by 2 h of reperfusion according to the protocol described by Yildirim and Albayrak18. The IR + hesperidin group (IR + Hes; n = 10) received a single oral dose of hesperidin (100 mg/kg) by oral gavage 30 min before tourniquet application and was subsequently subjected to the same 2 h ischemia and 2 h reperfusion protocol used for the IR group.

At the end of the reperfusion period, the animals were euthanized, and whole blood was collected into lithium-heparin tubes. Plasma was separated by centrifugation at 1,400 × g for 10 min and stored at −25 °C until biochemical analysis. The left gastrocnemius muscle was excised and divided into three portions. One portion was fixed in 10% neutral-buffered formalin for histological examination; a second portion was snap-frozen and stored at −80 °C for RNA extraction; and a third portion was homogenized and stored at −25 °C for biochemical analyses.

Biochemical analyses

Blood samples were centrifuged at 1,400 × g for 10 min, and the resulting aliquots were stored at −25°C until analysis. Alkaline phosphatase (ALP), creatine kinase (CK), and lactate dehydrogenase (LDH) concentrations were quantified using commercially available enzyme-linked immunosorbent assay (ELISA) kits with detection ranges of 1.25–80 ng/mL, 31.25–2,000 pg/mL, and 1.563–100 ng/mL, respectively. All assays were performed according to the manufacturer's instructions.

Histological examination

Following euthanasia, the left gastrocnemius muscle was dissected and fixed in 10% neutral buffered formalin for a minimum of 24 h. The tissues were processed using standard histological procedures, embedded in paraffin, sectioned at 3 µm, and stained with hematoxylin and eosin for microscopic examination. For semiquantitative assessment of muscle injury, five randomly selected fields per section were examined at 400× magnification by two independent pathologists blinded to the experimental groups. Muscle injury was graded using a 5-point scoring system based on the degree of muscle fiber degeneration19, as follows: grade 0 (normal architecture), grade 1 (mild: isolated fibers with loss of striations), grade 2 (moderate: multiple degenerating fibers with interstitial widening), grade 3 (severe: widespread necrosis with marked edema and inflammation), and grade 4 (extremely severe: extensive necrosis with massive interstitial hemorrhage).

ELISA analysis of muscle homogenates

Gastrocnemius muscle samples were homogenized in ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS). The lysis buffer was supplemented with a protease inhibitor cocktail containing 1 mM phenylmethylsulfonyl fluoride, 1 µg/mL aprotinin, 1 µg/mL leupeptin, and 1 µg/mL pepstatin A. The homogenates were centrifuged at 12,000 × g for 15 min at 4 °C, and the resulting supernatants were collected and stored at −80 °C until analysis.

Commercially available ELISA kits were used to quantify markers of oxidative stress, antioxidant capacity, inflammatory responses, and apoptosis. The oxidative stress and antioxidant parameters assessed were superoxide dismutase (SOD; 0.16–10 ng/mL), catalase (CAT; 0.79–50 ng/mL), malondialdehyde (MDA; 31.25–2,000 ng/mL), and glutathione peroxidase (GPx; 15.63–1,000 pg/mL). Components associated with antioxidant signaling included nuclear factor erythroid 2-related factor 2 (Nrf2; 0.16–10 ng/mL), heme oxygenase-1 (HO-1; 0.16–10 ng/mL), and NAD(P)H quinone dehydrogenase 1 (NQO1; 46.875–3,000 pg/mL).

The inflammatory mediators assessed were nuclear factor kappa B (NF-κB; 0.16–10 ng/mL), tumor necrosis factor alpha (TNF-α; 15.63–1,000 pg/mL), interleukin-6 (IL-6; 7.82–500 pg/mL), and interleukin-1 beta (IL-1β; 15.63–1,000 pg/mL). Apoptosis- and pyroptosis-associated proteins included caspase-3 (0.313–20 ng/mL), Bax (0.16–10 ng/mL), and NLR family pyrin domain containing 3 (NLRP3; 0.312–20 ng/mL). All measurements were performed according to the manufacturer's instructions.

Quantitative PCR for caspase-1

Total RNA was isolated from frozen gastrocnemius muscle homogenates using a phenol-guanidine-based RNA isolation reagent followed by purification with a silica membrane-based RNA purification method. Complementary DNA (cDNA) was synthesized from 8 µL of RNA using a reverse transcription system. Quantitative polymerase chain reaction (qPCR) was subsequently performed using a real-time PCR system, with β-actin serving as the internal reference gene. The reaction mixture (20 µL total volume) consisted of 10 µL of 2× SYBR Green PCR Master Mix, 2 µL of cDNA template, 1 µL each of forward and reverse primers (10 µM), and 6 µL of RNase-free water. The cycling protocol included an initial denaturation at 95 °C for 10 min, followed by 40 cycles of denaturation at 95 °C for 15 s, annealing at 60 °C for 30 s, and extension at 72 °C for 30 s. A melt curve analysis was performed from 65 °C to 95 °C in 0.5 °C increments to verify amplification specificity. Each sample was run in duplicate, and no-template controls (NTCs) and no-reverse-transcription controls (NRTs) were included in each run. Amplification efficiency for each primer pair was determined from a standard curve (fourfold dilution series of pooled cDNA) and ranged from 90–105%. Relative caspase-1 expression was calculated using the 2−ΔΔCT method described by Livak and Schmittgen20. The primer sequences used for qPCR were as follows: caspase-1 forward, 5′-GACCGAGTGGTTCCCTCAAG-3′; caspase-1 reverse, 5′-GACGTGTACGAGTGGGTGTT-3′; β-actin forward, 5′-CCGAGATCTCACCGACTACCTCA-3′; and β-actin reverse, 5′-TCAAAGTCCAGAGCGACATAGCA-3′.

Statistical analysis

All statistical analyses were performed using statistical analysis software. The group size of 10 animals per experimental condition was determined prospectively using dedicated power-analysis software, with an effect size of 0.8, a significance level of α = 0.05, and a desired statistical power of 0.80.

Before parametric analyses were performed, normality and homogeneity of variance were evaluated using the Shapiro–Wilk and Levene's tests, respectively. Both tests yielded p > 0.05, supporting the use of parametric statistical procedures. Comparisons among the four experimental groups were therefore performed using one-way analysis of variance (ANOVA), followed by Tukey's multiple-comparison test for post hoc pairwise comparisons. A p-value < 0.05 was considered statistically significant. All quantitative data were expressed as mean ± standard deviation (SD).

Access restricted. Please log in or start a trial to view this content.

Results

Improvement of ischemia–reperfusion-induced histological alterations by hesperidin

Histological examination of the gastrocnemius muscle revealed regularly arranged longitudinal muscle fibers in the control and hesperidin groups (Figure 1A–D). In contrast, the ischemia–reperfusion (IR) group exhibited marked muscle fiber degeneration and increased intercellular spacing (Figure 1E,F). C...

Access restricted. Please log in or start a trial to view this content.

Discussion

Tourniquet-induced ischemia remains a standard technique in many surgical specialties, particularly orthopedics, to obtain a bloodless operative field and improve visualization. Despite its utility, this approach inevitably produces localized ischemic stress followed by reperfusion injury, which can adversely affect several postoperative outcomes21. Although advances in tourniquet design and evidence-based application strategies have reduced certain complications22, no clin...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Generative artificial intelligence (AI) technologies, including ChatGPT (OpenAI), Claude (Anthropic), and SciSpace, were used solely for language refinement, literature organization, and editorial assistance during manuscript preparation. All scientific content, interpretations, citations, references, and conclusions were independently reviewed, verified, and approved by the author, who assumes full responsibility for the accuracy and integrity of the manuscript.

Acknowledgements

The authors extend their appreciation to Umm Al-Qura University, Saudi Arabia for funding this research work through grant number 26UQU4400419GSSR01.

Funding Statement
This research work was funded by Umm Al-Qura University, Saudi Arabia under grant number 26UQU4400419GSSR01.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
ALP ELISA Kit (1.25–80 ng/mL)ELK Biotechnology, ChinaELK5657https://www.elkbiotech.com/product/ELK5657
AprotininSigma-Aldrich, USAA6279https://www.sigmaaldrich.com/US/en/product/sigma/a6279
Bax ELISA Kit (0.16–10 ng/mL)Novus Biologicals, USANBP2-69938https://www.novusbio.com/products/nbp2-69938
β-actin Forward Primer (5′-CCGAGATCTCACCGACTACCTCA-3′)Integrated DNA Technologies, USACustomhttps://www.idtdna.com
β-actin Reverse Primer (5′-TCAAAGTCCAGAGCGACATAGCA-3′)Integrated DNA Technologies, USACustomhttps://www.idtdna.com
Carboxymethylcellulose (CMC), 0.5%Sigma-Aldrich, USAC5678https://www.sigmaaldrich.com/US/en/product/sigma/c5678
Caspase-1 Forward Primer (5′-GACCGAGTGGTTCCCTCAAG-3′)Integrated DNA Technologies, USACustomhttps://www.idtdna.com
Caspase-1 Reverse Primer (5′-GACGTGTACGAGTGGGTGTT-3′)Integrated DNA Technologies, USACustomhttps://www.idtdna.com
Caspase-3 ELISA Kit (0.313–20 ng/mL)Wuhan Fine Biotech Co., Ltd., ChinaER0143https://www.finebiotech.com/product/ER0143
CAT ELISA Kit (0.79–50 ng/mL)ELK Biotechnology, ChinaELK5986https://www.elkbiotech.com/product/ELK5986
CentrifugeEppendorf, Germany5810 Rhttps://www.eppendorf.com/us-en/lab-equipment/centrifuges/5810-5810-r-centrifuges
CK ELISA Kit (31.25–2000 pg/mL)Abcam, UKab285275https://www.abcam.com/products/ab285275
Dimethyl sulfoxide (DMSO), 5%Sigma-Aldrich, USAD8418https://www.sigmaaldrich.com/US/en/product/sigma/d8418
Eosin YSigma-Aldrich, USA318906https://www.sigmaaldrich.com/US/en/product/aldrich/318906
Ethanol (100%, 96%, 70%)Sigma-Aldrich, USA32205https://www.sigmaaldrich.com/US/en/product/aldrich/32205
Formalin, 10% neutral bufferedSigma-Aldrich, USAHT501128https://www.sigmaaldrich.com/US/en/product/sigma/ht501128
G*Power 3.1Heinrich Heine University Düsseldorf, GermanyN/Ahttps://www.psychologie.hhu.de/arbeitsgruppen/allgemeine-psychologie-und-arbeitspsychologie/gpower
GPx ELISA Kit (15.63–1000 pg/mL)ELK Biotechnology, ChinaELK2222https://www.elkbiotech.com/product/ELK2222
GraphPad Prism 8.0GraphPad Software, USAN/Ahttps://www.graphpad.com
HematoxylinSigma-Aldrich, USAHHS128https://www.sigmaaldrich.com/US/en/product/sigma/hhs128
HesperidinSigma-Aldrich, USAH5254https://www.sigmaaldrich.com/US/en/product/sigma/h5254
HO-1 ELISA Kit (0.16–10 ng/mL)ELK Biotechnology, ChinaELK1477https://www.elkbiotech.com/product/ELK1477
IL-1β ELISA Kit (15.63–1000 pg/mL)ELK Biotechnology, ChinaELK1272https://www.elkbiotech.com/product/ELK1272
IL-6 ELISA Kit (7.82–500 pg/mL)ELK Biotechnology, ChinaELK1158https://www.elkbiotech.com/product/ELK1158
KetamineSigma-Aldrich, USAK2753https://www.sigmaaldrich.com/US/en/product/sigma/k2753
LDH ELISA Kit (1.563–100 ng/mL)Wuhan Fine Biotech Co., Ltd., ChinaER0647https://www.finebiotech.com/product/ER0647
LeupeptinSigma-Aldrich, USAL2884https://www.sigmaaldrich.com/US/en/product/sigma/l2884
Light microscopeOlympus, JapanBX53https://www.olympus-lifescience.com/en/microscopes/bx53/
Lithium heparin tubesBD Vacutainer, USA367886https://www.bd.com/en-us/products/blood-collection
MDA ELISA Kit (31.25–2000 ng/mL)ELK Biotechnology, ChinaELK10920https://www.elkbiotech.com/product/ELK10920
MicrotomeLeica Biosystems, GermanyRM2255https://www.leicabiosystems.com/us/histology-equipment/microtomes/
Microsoft ExcelMicrosoft Corporation, USAN/Ahttps://www.microsoft.com/en-us/microsoft-365/excel
NF-κB ELISA Kit (0.16–10 ng/mL)ELK Biotechnology, ChinaELK1693https://www.elkbiotech.com/product/ELK1693
NLRP3 ELISA Kit (0.312–20 ng/mL)Novus Biologicals, USANBP3-42294https://www.novusbio.com/products/nbp3-42294
NQO1 ELISA Kit (46.875–3000 pg/mL)MyBioSource, USAMBS7606601https://www.mybiosource.com/product/MBS7606601
Nrf2 ELISA Kit (0.16–10 ng/mL)ELK Biotechnology, ChinaELK8043https://www.elkbiotech.com/product/ELK8043
Paraffin waxSigma-Aldrich, USA327204https://www.sigmaaldrich.com/US/en/product/aldrich/327204
Pepstatin ASigma-Aldrich, USAP5318https://www.sigmaaldrich.com/US/en/product/sigma/p5318
Protease inhibitor cocktail (PMSF)Sigma-Aldrich, USAP7626https://www.sigmaaldrich.com/US/en/product/sigma/p7626
QIAzol Lysis ReagentQiagen, Germany79306https://www.qiagen.com/us/products/discovery-and-translational-research/dna-rna-purification/rna-purification/total-rna/qiazol-lysis-reagent
QuantiTect Reverse Transcription KitQiagen, Germany205311https://www.qiagen.com
RIPA lysis bufferThermo Fisher Scientific, USA89900https://www.thermofisher.com/order/catalog/product/89900
RNeasy Mini KitQiagen, Germany74104https://www.qiagen.com/us/products/discovery-and-translational-research/dna-rna-purification/rna-purification/total-rna/rneasy-mini-kit
Rotor-Gene QQiagen, Germany9001571https://www.qiagen.com
Sodium chloride, 0.9%Sigma-Aldrich, USAS7653https://www.sigmaaldrich.com/US/en/product/sigma/s7653
SOD ELISA Kit (0.16–10 ng/mL)ELK Biotechnology, ChinaELK8178https://www.elkbiotech.com/product/ELK8178
TissueLyser IIQiagen, Germany85300https://www.qiagen.com
TNF-α ELISA Kit (15.63–1000 pg/mL)ELK Biotechnology, ChinaELK1396https://www.elkbiotech.com/product/ELK1396
Type IV cageBioscape, GermanyN/Ahttps://www.bioscape.de
XyleneSigma-Aldrich, USA214736https://www.sigmaaldrich.com/US/en/product/aldrich/214736
XylazineSigma-Aldrich, USAX1251https://www.sigmaaldrich.com/US/en/product/sigma/x1251

References

  1. Haglund U, Lundgren O. Intestinal ischemia and shock factors. Federation Proceedings. 1978;37(13):2729-2733.
  2. Blaisdell FW. The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. Cardiovascular Surgery. 2002;10(6):620-630.
  3. Saied A, Zyaei A. Tourniquet use during plating of acute extra-articular tibial fractures: effects on final results of the operation. The Journal of Trauma. 2010;69(6):E94–E97.
  4. Konrad G, Markmiller M, Lenich A, Mayr E, Rüter A. Tourniquets may increase postoperative swelling and pain after internal fixation of ankle fractures. Clinical Orthopaedics and Related Research. 2005;(433):189-194.
  5. Kirkley A, et al. Tourniquet versus no tourniquet use in routine knee arthroscopy: a prospective, double-blind, randomized clinical trial. Arthroscopy. 2000;16(2):121-126.
  6. Ejaz A, et al. Faster recovery without the use of a tourniquet in total knee arthroplasty. Acta Orthopaedica. 2014;85(4):422-426.
  7. Anzell AR, Maizy R, Przyklenk K, Sanderson TH. Mitochondrial quality control and disease: insights into ischemia-reperfusion injury. Molecular Neurobiology. 2018;55(3):2547-2564.
  8. Toyokuni S. Reactive oxygen species-induced molecular damage and its application in pathology. Pathology International. 1999;49(2):91-102.
  9. Carden DL, Granger DN. Pathophysiology of ischaemia-reperfusion injury. The Journal of Pathology. 2000;190(3):255-266.
  10. Collard CD, et al. Complement activation following oxidative stress. Molecular Immunology. 1999;36(13-14):941-948.
  11. Panés J, Perry M, Granger DN. Leukocyte-endothelial cell adhesion: avenues for therapeutic intervention. British Journal of Pharmacology. 1999;126(3):537-550.
  12. Rong Z, et al. Hesperidin pretreatment protects hypoxia-ischemic brain injury in neonatal rat. Neuroscience. 2013;255:292-299.
  13. Wei D, et al. Hesperidin suppresses ovalbumin-induced airway inflammation in a mouse allergic asthma model. Inflammation. 2012;35(1):114-121.
  14. Kaur G, Tirkey N, Chopra K. Beneficial effect of hesperidin on lipopolysaccharide-induced hepatotoxicity. Toxicology. 2006;226(2-3):152-160.
  15. Apaydin Yildirim B, Albayrak S. Protective effects of crocin on experimental gastrocnemius muscle ischemia/reperfusion model in rat. The Eurasia Proceedings of Science, Technology, Engineering & Mathematics. 2018;3:116-120. Available from: https://epstem.net/index.php/epstem/article/view/129
  16. Pottecher J, et al. Skeletal muscle ischemia-reperfusion injury and cyclosporine A in the aging rat. Fundamental & Clinical Pharmacology. 2016;30(3):216-225.
  17. Park HK, Kang SW, Park MS. Hesperidin ameliorates hepatic ischemia-reperfusion injury in Sprague-Dawley rats. Transplantation Proceedings. 2019;51(8):2828-2832.
  18. Yildirim BA, Albayrak S. Effect of crocin on experimental gastrocnemius muscle ischemia/reperfusion injury in rat. Veterinary Research Forum. 2023;14(4):201-206.
  19. Jaćević V, Nepovimova E, Kuča K. Toxic injury to muscle tissue of rats following acute oximes exposure. Scientific Reports. 2019;9(1):1457.
  20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402-408.
  21. Liu D, Graham D, Gillies K, Gillies RM. Effects of tourniquet use on quadriceps function and pain in total knee arthroplasty. Knee Surgery & Related Research. 2014;26(4):207-213.
  22. Estebe JP, Davies JM, Richebe P. The pneumatic tourniquet: mechanical, ischaemia-reperfusion and systemic effects. European Journal of Anaesthesiology. 2011;28(6):404-411.
  23. Park UJ, et al. Remote ischemic preconditioning enhances the expression of genes encoding antioxidant enzymes and endoplasmic reticulum stress-related proteins in rat skeletal muscle. Vascular Specialist International. 2016;32(4):141-149.
  24. Herrero de la Parte B, et al. The prevention of ischemia-reperfusion injury in elderly rats after lower limb tourniquet use. Antioxidants. 2022;11(10):1936.
  25. Abdel-Raheem IT, Abdel-Ghany AA. Hesperidin alleviates doxorubicin-induced cardiotoxicity in rats. Journal of the Egyptian National Cancer Institute. 2009;21(2):175-184.
  26. Suarez J, Herrera MD, Marhuenda E. In vitro scavenger and antioxidant properties of hesperidin and neohesperidin dihydrochalcone. Phytomedicine. 1998;5(6):469-473.
  27. Xin S, et al. Therapeutic potential of hesperidin in diabetes mellitus-induced erectile dysfunction through Nrf2-mediated ferroptosis and oxidative stress. Andrology. 2025;13(7):1702-1714.
  28. Kim J, Cha YN, Surh YJ. A protective role of nuclear factor-erythroid 2-related factor-2 (Nrf2) in inflammatory disorders. Mutation Research. 2010;690(1-2):12-23.
  29. Jiang T, et al. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. Kidney International. 2014;85(2):333-343.
  30. Song X, et al. Resveratrol alleviates vascular endothelial damage caused by lower-extremity ischemia reperfusion (I/R) through regulating Keap1/Nrf2 signaling-mediated oxidative stress. Evidence-Based Complementary and Alternative Medicine. 2021;2021:5556603.
  31. Andrade-Silva AR, et al. Effect of NFkappaB inhibition by CAPE on skeletal muscle ischemia-reperfusion injury. Journal of Surgical Research. 2009;153:254-262.
  32. Liu P, et al. Hesperetin modulates the Sirt1/Nrf2 signaling pathway in counteracting myocardial ischemia through suppression of oxidative stress, inflammation, and apoptosis. Biomedicine & Pharmacotherapy. 2021;139:111552.
  33. Meng X, et al. The protective effect of hesperidin against renal ischemia-reperfusion injury involves the TLR-4/NF-κB/iNOS pathway in rats. Physiology International. 2020;107(1):82-91.
  34. Huang Q, et al. Hesperidin ameliorates H2O2-induced bovine mammary epithelial cell oxidative stress via the Nrf2 signaling pathway. Journal of Animal Science and Biotechnology. 2024;15(1):57.
  35. Latz E. The inflammasomes: mechanisms of activation and function. Current Opinion in Immunology. 2010;22(1):28-33.
  36. Sandanger Ø, et al. The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovascular Research. 2013;99(1):164-174.
  37. Sun HJ, et al. NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell Death & Disease. 2017;8(10).
  38. Artlett CM, Thacker JD. Molecular activation of the NLRP3 inflammasome in fibrosis: common threads linking divergent fibrogenic diseases. Antioxidants & Redox Signaling. 2015;22(13):1162-1175.
  39. Xie L, et al. The anti-depressive effects of hesperidin and the relative mechanisms based on the NLRP3 inflammatory signaling pathway. Frontiers in Pharmacology. 2020;11:1251.
  40. Gao S, et al. Remote limb ischaemic postconditioning protects against myocardial ischaemia/reperfusion injury in mice: activation of JAK/STAT3-mediated Nrf2-antioxidant signalling. Cellular Physiology and Biochemistry. 2017;43(3):1140-1151.
  41. Zuo L, et al. Biological and physiological role of reactive oxygen species—the good, the bad and the ugly. Acta Physiologica. 2015;214(3):329-348.
  42. Li S, et al. Hesperidin ameliorates liver ischemia/reperfusion injury via activation of the Akt pathway. Molecular Medicine Reports. 2020;22(6):4519-4530.

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

Skeletal Muscle InjuryHesperidin TreatmentNrf2 PathwayNF-KappaB PathwayNLRP3 InflammasomeOxidative StressAntioxidant EnzymesMuscle Fiber DamageInflammatory Signaling